Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca

Feb 04 2019

• By Kevin Grogan, Jessica Merrill, and Mandy Jackson

4th quarter computer key on key board

Related Content

Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase

Jun 29 2018

Lilly Ready For More Risk When It Comes To Early Deals

Dec 19 2018

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

Lilly's New Year Resolution: Make New Launches Into Blockbusters

Dec 20 2018

GSK Embraces PARP Promise With Tesaro Buy

Dec 03 2018

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Mar 13 2018

AstraZeneca Rejig Brings Baselga On Board

Jan 07 2019

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

Jan 07 2019

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

Jan 07 2019

AZ Management Shake-Up Sees CMO Bohen Exit

Jan 14 2019

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Jan 21 2019

MyoKardia Frames End Of Sanofi Partnership As A Bet On Itself

Jan 02 2019

Generic Advair: Finally Approved, A Long Time Coming

Jan 30 2019

Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee

Jan 18 2019

Insulin Makers May Be First In Crosshairs Of DeGette Rx Pricing Investigation

Jan 17 2019

Sen. Grassley To Be "More Insistent" About Drug Firms' Testimony At Future Hearings

Jan 30 2019

Related Companies

Sanofi

Ablynx N.V.

Roche Holding AG

Regeneron Pharmaceuticals, Inc.

MyoKardia, Inc.

GSK plc

Tesaro, Inc.

Viatris Inc.

Eli Lilly and Company

Loxo Oncology at Lilly

AstraZeneca PLC

Additional Topics

Sales & Earnings Business Strategies Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window